Aeterna Zentaris Names New CEO

Aeterna Zentaris has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.

Dodd has been in the pharmaceutical and biotech industries for more than 35 years. He was CEO and chairman of BioReliance, now a unit of Sigma-Aldrich. He also served in various executive capacities for companies such as Serologicals (now a subsidiary of Millipore) and Solvay Pharmaceuticals, among other prominent firms in the industry.

The article Aeterna Zentaris Names New CEO originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.